98%
921
2 minutes
20
Background: Previous studies have suggested that factors such as the treatment interval and aetiology may influence the initial response rate to first-line treatment for infantile epileptic spasms syndrome (IESS). However, few children with IECSS have undergone clinically accessible tests to determine the aetiology.
Methods: Using a dataset from our previously published research, we constructed and tested a predictive model for the initial response to first-line treatment in children with IESS. Random sampling and 5-fold cross-validation were performed, with synthetic minority oversampling technique to correct data imbalance. Machine learning algorithms and evaluation metrics optimised model accuracy and efficacy.
Results: This study included 532 children with IESS who had completed monotherapy first-line treatment, of whom 160 achieved an initial response. The model's accuracy, F1 score, and area under the curve (AUC) in the validation set were 0.7836 ± 0.0229 (ranging from 0.75167 to 0.80536), 0.7833 ± 0.0229 (ranging from 0.75145 to 0.80531), and 0.8516 ± 0.0165 (ranging from 0.82468 to 0.86936), respectively. Factors such as the age of seizure onset, age of spasm onset, lead time, MRI subtype, treatment choice, and age at treatment consistently ranked in the top six for importance in contributing to the model.
Conclusions: The study findings suggest that this model may help effectively predict the initial response to first-line treatment, supporting clinical decision-making for children with IESS. Key predictors such as the age of seizure onset and MRI subtype enable early, data-driven intervention strategies in clinical practice.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11993986 | PMC |
http://dx.doi.org/10.1186/s13052-025-01959-z | DOI Listing |
J Healthc Sci Humanit
January 2024
Program Manager, Center for Biomedical Research/Research Centers in Minority Institutions (TU CBR/RCMI), Department of Biology, College of Arts and Sciences (CAS), Tuskegee University, Phone: (334) 724-4391, Email:
The emergence of the Novel COVID-19 Pandemic has undoubtedly impacted the lives of individuals across the globe. It has drawn the attention of major public health agencies as they work intensely towards understanding the behavior of the virus causing the disease, while simultaneously establishing ways to curb the spread of the virus among populations. As of the time of writing, 7,949,973 confirmed cases have been reported globally; with the United States (US) contributing to 26.
View Article and Find Full Text PDFClin Kidney J
September 2025
Department of Nephrology and Institute of Nephrology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Background: This study aimed to evaluate the efficacy and safety of telitacicept versus mycophenolate mofetil (MMF) in high-risk progressive immunoglobulin A nephropathy (IgAN).
Methods: This retrospective, multicentre cohort study included patients with high-risk progressive IgAN who received telitacicept or MMF therapy, both combined with low-dose steroids. Clinical data were collected from treatment initiation to 12 months.
J Inflamm Res
September 2025
The Second Clinical College of Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning Province, People's Republic of China.
Purpose: Autoimmune thyroiditis (AIT) is the most common organ-specific autoimmune disease, and its pathogenesis is closely related to the inflammatory microenvironment driven by immune cell penetration. The role of the newly proposed concept of PANoptosis in immune-related diseases is gradually being revealed. However, there is currently a lack of reports on PANoptosis in AIT.
View Article and Find Full Text PDFJ Immunother Precis Oncol
August 2025
Department of Medicine, Sylvester Comprehensive Cancer Center/University of Miami, Miami, FL, USA.
The combination of targeted therapies and immunotherapies for advanced and metastatic sarcomas has been proposed owing to the enhanced effect of antiangiogenic therapies on the tumor microenvironment. We found eight studies published to date assessing the effectiveness of combined multitargeted vascular endothelial growth factor (VEGF)-tyrosine kinase inhibitors with immune checkpoint inhibitors (ICIs) in sarcoma. It is difficult to draw conclusions owing to limited data and primarily single-arm studies, although initial literature appears promising and requires further study.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
September 2025
Department of Visceral, Thoracic and Vascular Surgery, Philipps University Marburg, Marburg, Germany.
Introduction: The prognosis of anaplastic thyroid carcinoma (ATC) remains poor. Mutation-based targeted therapies and immune checkpoint inhibitors (ICI) have gained increasing importance in the treatment of advanced tumor stages. This study aimed to investigate whether mutation-based neoadjuvant therapy can convert an initially unresectable tumor into a resectable state, optimizing local tumor control and prolonging overall survival.
View Article and Find Full Text PDF